Should thaldex (thalidomide-dexamethasone) replace VAD (vincristine-adriamycin-dexamethasone) as induction treatment for newly diagnosed multiple myeloma? The Indian perspective

被引：0
|
作者：
Pandey, Ritwik [1 ]
Patel, Kirti M. [1 ]
Shah, Sandip A. [1 ]
Patel, Apurva A. [1 ]
机构：
[1] Gujarat Canc Res Inst, Ahmadabad, Gujarat, India
来源：
ANNALS OF ONCOLOGY | 2007年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：181 / 181
页数：1
相关论文
共 50 条
  • [21] Sequential VAD (vincristine, adriamycin, dexamethasone) and VTD (VELCADE®, thalidomide, dexamethasone) induction followed by high-dose therapy with autologous stem cell transplantation and maintenance treatment with VELCADE for newly diagnosed multiple myeloma:: Interim results of phase II trial
    Yoon, Sung-Soo
    Kim, Hye Jin
    Lee, Dong Soon
    Eom, Hyeon Seok
    Jang, Jun Ho
    Chung, Ju Seup
    Kang, Hye Jin
    Kim, Cheol Soo
    Kim, Kihyun
    Lee, Jae Hoon
    Lee, Sang Jae
    Min, Yu Hong
    Seong, Chu Myong
    Sohn, Sang Kyun
    Suh, Cheolwon
    Won, Jong Ho
    BLOOD, 2007, 110 (11) : 290A - 290A
  • [22] SEQUENTIAL VAD (VINCRISTINE, ADRIAMYCIN, DEXAMETHASONE) AND VTD (BORTEZOMIB, THALIDOMIDE, DEXAMETHASONE) INDUCTION FOLLOWED BY HIGH-DOSE THERAPY WITH AUTOLOGOUS STEM CELL TRANSPLANTATION AND MAINTENANCE TREATMENT WITH BORTEZOMIB FOR NEWLY DIAGNOSED MULTIPLE MYELOMA: INTERIM RESULTS OF PHASE 11 TRIAL
    Yoon, S. S.
    Kim, H. J.
    Lee, D. S.
    Eom, H. S.
    Jang, J. H.
    Chung, J. S.
    Kang, H. J.
    Kim, C. S.
    Kim, K. K.
    Lee, J. H.
    Lee, S. J.
    Min, Y. H.
    Seong, C. M.
    Sohn, S. K.
    Suh, C.
    Won, J. H.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 86 - 87
  • [23] Sequential VAD (Vincristine, Adriamycin, Dexamethasone) and VTD (Bortezomib, Thalidomide, Dexamethasone) Induction Followed by High-Dose Therapy with Autologous Stem Cell Transplantation and Maintenance Treatment with Bortezomib for Newly Diagnosed Multiple Myeloma: Final Analysis of Phase II Trial
    Yoon, Suno-Soo
    Kim, Hye Jin
    Chung, Joo Seop
    Eom, HyeonSeok
    Jang, Jun-Ho
    Kang, Hye Jin
    Kim, Cheol Soo
    Kim, Kihyun
    Lee, Dongsoon
    Lee, Jae Hoon
    Lee, Junglim
    Lee, Sang Jae
    Min, Yoo Hong
    Seong, Chu-Myong
    Sohn, Sang-Kyun
    Suh, Cheolwon
    Won, Jong-Ho
    BLOOD, 2008, 112 (11) : 1144 - 1144
  • [24] Outpatient treatment of multiple myeloma with a combination of vincristine, Adriamycin and dexamethasone
    Egerer, G
    Hegenbart, U
    Salwender, H
    Haas, R
    Hahn, U
    Schmier, JW
    Ho, AD
    Goldschmidt, H
    SUPPORTIVE CARE IN CANCER, 2001, 9 (05) : 380 - 385
  • [25] Ambulant treatment of multiple myeloma with combined vincristine, adriamycin and dexamethasone
    Egerer, G
    Hegenbart, U
    Salwender, H
    Hahn, U
    Haas, R
    Goldschmidt, H
    Hunstein, W
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 1997, 122 (17) : 531 - 535
  • [26] THALIDOMIDE-DEXAMETHASONE (THALDEX) AS SALVAGE THERAPY FOR MULTIPLE MYELOMA PATIENTS RELAPSING AFTER HIGH DOSE THERAPY AND AUTOPBSCT
    Charlinski, G.
    Barwicka, M.
    Wiater, E.
    Dwilewicz-Trojaczek, J.
    Wiktor-Jedrzejczak, W.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 262 - 263
  • [27] Outpatient treatment of multiple myeloma with a combination of vincristine, adriamycin and dexamethasone
    Egerer G.
    Hegenbart U.
    Salwender H.
    Haas R.
    Hahn U.
    Schmier J.
    Ho A.
    Goldschmidt H.
    Supportive Care in Cancer, 2001, 9 (5) : 380 - 385
  • [28] Combination of TCD (thalidomide, cyclophosphamideand dexamethasone); An effective and safe alternative to conventional VAD (vincristine, adriamycin and dexamethasone) as a first-line therapy in multiple myeloma
    Kim, Y.-K.
    Lee, J. J.
    Sohn, S. K.
    Shin, H. J.
    Lee, S. R.
    Shim, H. J.
    Ahn, J. S.
    Yang, D. H.
    Cho, S. H.
    Chung, I. J.
    Kim, H. J.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 93 - 93
  • [29] BORTEZOMIB PLUS DEXAMETHASONE VERSUS REDUCED-DOSE BORTEZOMIB PLUS THALIDOMIDE-DEXAMETHASONE AS INDUCTION PRIOR TO AUTOLOGOUS TRANSPLANTATION IN NEWLY DIAGNOSED MYELOMA
    Harousseau, J. L.
    Avet-Loiseau, H.
    Mary, J.
    Facon, T.
    Attal, M.
    Doyen, C.
    Hulin, C.
    Garderet, L.
    Tiab, M.
    Lepeu, G.
    Araujo, C.
    Caillot, D.
    Petillon, M.
    Mathiot, C.
    Moreau, P.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 451 - 451
  • [30] Bortezomib (velcade(R))-thalidomide-dexamethasone (VTD) vs thalidomide-dexamethasone (TD) in preparation for autologous stem-cell (SC) transplantation (ASCT) in newly diagnosed multiple myeloma (MM)
    Cavo, Michele
    Patriarca, Francesca
    Tacchetti, Paola
    Galli, Monica
    Perrone, Giulia
    Petrucci, Maria Teresa
    Brioli, Annamaria
    Bringhen, Sara
    Pantani, Lucia
    Tosi, Patrizia
    Crippa, Claudia
    Zamagni, Elena
    Di Raimondo, Francesco
    Narni, Franco
    Cellini, Claudia
    Ceecolini, Michela
    Pescosta, Norbert
    Goldaniga, Maria Cecilia
    Montefusco, Vittorio
    Callea, Vincenzo
    De Stefano, Valerio
    Caravita, Tommaso
    Boccadoro, Mario
    Baccarani, Michele
    BLOOD, 2007, 110 (11) : 30A - 30A
12345